Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $798,976.97 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Patrick Harrison Carroll sold 23,287 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $34.31, for a total value of $798,976.97. Following the sale, the insider now directly owns 209,661 shares of the company’s stock, valued at approximately $7,193,468.91. This represents a 10.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Hims & Hers Health Price Performance

HIMS stock traded down $3.23 during mid-day trading on Tuesday, reaching $31.46. 15,228,182 shares of the company traded hands, compared to its average volume of 13,542,813. The company has a market capitalization of $6.99 billion, a P/E ratio of 71.49 and a beta of 1.37. Hims & Hers Health, Inc. has a 52-week low of $11.20 and a 52-week high of $72.98. The company has a fifty day moving average price of $38.64 and a 200-day moving average price of $28.37.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. As a group, analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on HIMS. Truist Financial raised their target price on Hims & Hers Health from $24.00 to $39.00 and gave the company a “hold” rating in a research report on Wednesday, February 26th. TD Cowen restated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. BTIG Research initiated coverage on Hims & Hers Health in a research note on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective on the stock. Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday, February 19th. Finally, Citigroup restated a “sell” rating and issued a $27.00 price objective on shares of Hims & Hers Health in a research note on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $37.31.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HIMS. Principal Financial Group Inc. grew its holdings in shares of Hims & Hers Health by 102.0% during the third quarter. Principal Financial Group Inc. now owns 290,414 shares of the company’s stock worth $5,349,000 after purchasing an additional 146,621 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of Hims & Hers Health by 164.9% during the third quarter. Victory Capital Management Inc. now owns 51,577 shares of the company’s stock worth $950,000 after purchasing an additional 32,108 shares in the last quarter. Royce & Associates LP grew its holdings in shares of Hims & Hers Health by 17.0% during the third quarter. Royce & Associates LP now owns 341,000 shares of the company’s stock worth $6,281,000 after purchasing an additional 49,500 shares in the last quarter. Quest Partners LLC boosted its stake in Hims & Hers Health by 22.6% in the third quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock worth $81,000 after buying an additional 807 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Hims & Hers Health in the third quarter worth approximately $1,064,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.